Identification of a Specific Reprogramming-associated Epigenetic Signature in Human Induced Pluripotent Stem Cells
Overview
Authors
Affiliations
Generation of human induced pluripotent stem cells (hiPSCs) by the expression of specific transcription factors depends on successful epigenetic reprogramming to a pluripotent state. Although hiPSCs and human embryonic stem cells (hESCs) display a similar epigenome, recent reports demonstrated the persistence of specific epigenetic marks from the somatic cell type of origin and aberrant methylation patterns in hiPSCs. However, it remains unknown whether the use of different somatic cell sources, encompassing variable levels of selection pressure during reprogramming, influences the level of epigenetic aberrations in hiPSCs. In this work, we characterized the epigenomic integrity of 17 hiPSC lines derived from six different cell types with varied reprogramming efficiencies. We demonstrate that epigenetic aberrations are a general feature of the hiPSC state and are independent of the somatic cell source. Interestingly, we observe that the reprogramming efficiency of somatic cell lines inversely correlates with the amount of methylation change needed to acquire pluripotency. Additionally, we determine that both shared and line-specific epigenetic aberrations in hiPSCs can directly translate into changes in gene expression in both the pluripotent and differentiated states. Significantly, our analysis of different hiPSC lines from multiple cell types of origin allow us to identify a reprogramming-specific epigenetic signature comprised of nine aberrantly methylated genes that is able to segregate hESC and hiPSC lines regardless of the somatic cell source or differentiation state.
Sarami I, Hekman K, Gupta A, Snider J, Ivancic D, Zec M bioRxiv. 2025; .
PMID: 40060393 PMC: 11888470. DOI: 10.1101/2025.02.27.640060.
Reed X, Weller C, Saez-Atienzar S, Beilina A, Solaiman S, Portley M bioRxiv. 2024; .
PMID: 39713361 PMC: 11661179. DOI: 10.1101/2024.12.13.627515.
Advanced patient-specific microglia cell models for pre-clinical studies in Alzheimer's disease.
Cuni-Lopez C, Stewart R, Oikari L, Nguyen T, Roberts T, Sun Y J Neuroinflammation. 2024; 21(1):50.
PMID: 38365833 PMC: 10870454. DOI: 10.1186/s12974-024-03037-3.
Metabolic control of induced pluripotency.
Sinenko S, Tomilin A Front Cell Dev Biol. 2024; 11:1328522.
PMID: 38274274 PMC: 10808704. DOI: 10.3389/fcell.2023.1328522.
Incomplete reprogramming of DNA replication timing in induced pluripotent stem cells.
Edwards M, Wang N, Massey D, Bhatele S, Egli D, Koren A Cell Rep. 2024; 43(1):113664.
PMID: 38194345 PMC: 11231959. DOI: 10.1016/j.celrep.2023.113664.